BioAtla Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 07:13

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec V), a CAB AXL ADC, at the[...]